| Literature DB >> 14602189 |
Philippe Bourget1, Angelo Paci, Jean Baptiste Rey, Lionel Mercier, Sylvie Demirdjian.
Abstract
The Department of Clinical Pharmacy (DCP) in the Institut Gustave-Roussy (IGR) is equipped with a high-performance thin-layer chromatography (HPTLC) analytical platform. One of the numerous possible uses of HPTLC is post-production quality control of chemotherapy manufacturing. After 3 years of existence, routine validation of manufactured batches has attained considerable maturity: 24 cytotoxic agents can be controlled in terms of identity, purity and concentration. Approximately 50% of the sampled preparations are assessed. More than 97% were within specifications, 1.6% were not, probably due to incorrect homogenization before sampling; and 1% were not evaluable. Using HPTLC in a hospital manufacturing unit contributes to quality assurance programmes such as accreditation to which the IGR DCP is now committed but also ISO 9001:2000 certification concerning the chemotherapy manufacturing unit.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14602189 DOI: 10.1016/s0939-6411(03)00117-6
Source DB: PubMed Journal: Eur J Pharm Biopharm ISSN: 0939-6411 Impact factor: 5.571